EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf571 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Bojan Kovacevic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastro Unit, Division of Endoscopy, Copenhagen University Hospital Herlev and Gentofte, DK-2730 Herlev, Denmark. Hauptthemen laut MEDLINE: Insulinoma, Radiofrequency Ablation, Pancreatic Neoplasms, Endosonography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Copenhagen University Hospital Herlev and Gentofte.
Abstract (Originalsprache)
Context
Insulinomas, although rare, are among the most common functional pancreatic neuroendocrine neoplasms (pNENs), causing debilitating and recurrent hypoglycemic episodes and severely affecting quality of life.
Objective
To evaluate endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as a novel and minimally invasive treatment for insulinomas. Patients We retrospectively identified patients at a single tertiary care center between 2022 and 2025 with a suspicion of insulinomas (based on a positive fasting test and imaging) who underwent EUS-RFA. Lesions considered for RFA were biopsy-proven pNENs with a Ki-67 index <10%, and <25 mm in size. All patients were hospitalized for 24 hours and EUS-RFA was conducted under general anesthesia using a dedicated EUS-RFA needle and under direct ultrasound guidance. Mean follow-up duration was 15.5 months. The primary outcome measure was clinical success (symptom improvement with a documented increase in blood glucose) and safety.
Results
A total of 17 patients were identified and included. The mean age was 60.1 years and 53% were male. Normoglycemia was achieved after a single EUS-RFA session in 11 patients (64.7%), while 6 patients (35.3%) required a second EUS-RFA. The overall clinical success rate was 100% (n = 17/17; 95% CI: 80.4%-100.0%). A total of 4 adverse events were observed in 23 procedures (17.4%), 2 mild and 2 moderate (8.7%).
Conclusion
EUS-RFA appears to provide complete symptom resolution and demonstrates a favorable safety profile compared to conventional surgery. However, the long-term efficacy of EUS-RFA remains to be determined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastro Unit, Division of Endoscopy, Copenhagen University Hospital Herlev and Gentofte, DK-2730 Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark.
- Department of Nephrology and Endocrinology, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark.
- ENETS center of Excellence, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark.
- Department of Internal Medicine, Copenhagen University Hospital Herlev and Gentofte, DK-2730 Herlev, Denmark.
ORCID-Profile: Bojan Kovacevic, Peter Vilmann, Lene Brink, Marianne Christina Klose, Ulrich Knigge, Mikkel Andreassen
Förderung
- Copenhagen University Hospital Herlev and Gentofte
Zitieren
APA
Kovacevic, B., Vilmann, P., Brink, L., Klose, M. C., Sonne, M. P., Knigge, U., & Andreassen, M. (2026). EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf571
Vancouver
Kovacevic B, Vilmann P, Brink L, Klose MC, Sonne MP, Knigge U, et al. EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf571
BibTeX
@article{Kovacevic2026,
author = {Kovacevic, Bojan and Vilmann, Peter and Brink, Lene and Klose, Marianne Christina and Sonne, Mette Paulli and Knigge, Ulrich and Andreassen, Mikkel},
title = {EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf571}
}
EUVIMED